Meeting Details

The Thirty First Annual General Meeting of Zydus Lifesciences Limited was held on Tuesday, August 11, 2026, through Video Conferencing/Other Audio Visual Means. The meeting commenced at 10:00 a.m. IST and concluded at 11:16 a.m. IST.

Attendance

Shareholder Representation: 74,79,96,033 shares representing 74.99% of total paid-up equity share capital

Physical Attendance: 106 members including bodies corporate through representatives

Directors and Key Personnel Present:

  • Mr. Pankaj R. Patel - Chairman
  • Dr. Sharvil P. Patel - Managing Director
  • Mr. Ganesh N. Nayak - Director
  • Mr. Bhadresh K. Shah - Independent Director and Chairman of Nomination and Remuneration Committee
  • Ms. Shelina P. Parikh - Independent Woman Director
  • Mr. Akhil A Monappa - Independent Director and Chairman of Audit Committee
  • Mr. Kulin S. Lalbhai - Independent Director
  • Mr. Mukesh M. Patel - Non-Executive Director and Chairman of Stakeholders'/Investors' Relationship Committee
  • Mr. Tushar D. Shroff - Chief Financial Officer
  • Mr. Dhaval N. Soni - Company Secretary and Compliance Officer
  • Mr. Kartikeya Raval - Partner, Deloitte Haskins & Sells LLP (Statutory Auditors)
  • Mr. Ashish Doshi - Secretarial Auditor and Scrutinizer

Meeting Proceedings

Mr. Pankaj R. Patel chaired the meeting and welcomed members. The Chairman briefed members about business performance, financial highlights, and major developments during FY ended March 31, 2026. The notice of AGM dated May 19, 2026, was taken as read. There were no qualifications or adverse remarks in the Auditor's Report requiring reading during the AGM.

Shareholder Queries

Members asked questions regarding:

  • Plans to expand capacity
  • Lower standalone results
  • Company's shareholding in Assertio (acquired entity)
  • Growth prospects of domestic business
  • Export turnover and hedge strategy
  • Global biosimilar strategy
  • Plans to reduce debt
  • Handling US pricing, regulatory and market pressures
  • USFDA inspections at manufacturing facilities
  • Plans for further acquisitions (inorganic growth)
  • Overall R&D spends
  • Plan to repay debt
  • Effect of US tariffs on business

The Chairman and Managing Director responded to all questions with adequate details and provided general guidance on future prospects.

Voting Process

The company used CDSL's remote e-voting platform. Mr. Ashish Doshi, Practicing Company Secretary (Membership No. 3544), was appointed as Scrutinizer for both remote e-voting and e-voting during AGM.

Resolutions Approved

All nine resolutions were approved through remote e-voting and e-voting during AGM:

Ordinary Business:

1. Adoption of Audited Standalone Financial Statements for FY ended March 31, 2026 - 99.9999% in favor

2. Adoption of Audited Consolidated Financial Statements for FY ended March 31, 2026 - 99.9999% in favor

3. Declaration of Final Dividend of ₹1.00 (100%) per equity share for FY ended March 31, 2026 - 99.9999% in favor

4. Re-appointment of Mr. Pankaj R. Patel (DIN: 00131852) - 99.6349% in favor

5. Re-appointment of Mr. Mukesh M. Patel (DIN: 00053892) - 98.7213% in favor

Special Business:

6. Ratification of remuneration to Cost Auditors (R. Nanabhoy & Co.) - ₹1 million plus GST and out-of-pocket expenses for FY ending March 31, 2027 - 99.9997% in favor

7. Re-appointment of Dr. Sharvil P. Patel (DIN: 00131995) as Managing Director for 5 years from April 1, 2027 to March 31, 2032 - 95.6686% in favor

8. Appointment of Mr. Kulin S. Lalbhai (DIN: 05206878) as Independent Director for 5 years from May 19, 2026 - 90.4413% in favor

9. Payment of commission to non-executive directors not exceeding 1% of net profits or ₹40 million per annum for 5 years from April 1, 2026 to March 31, 2031 - 99.9859% in favor

Key Appointments and Terms

Dr. Sharvil P. Patel's Re-appointment:

  • Term: 5 years (April 1, 2027 to March 31, 2032)
  • Remuneration within limits prescribed under Companies Act and SEBI Listing Regulations
  • Entitled to provident fund, gratuity, leave encashment, personal accident insurance, medical premiums, car with driver, and other company policy benefits

Mr. Kulin S. Lalbhai's Appointment:

  • Term: 5 years from May 19, 2026
  • Not liable to retire by rotation

Dividend Details

Final dividend of ₹1.00 per equity share (100%) declared for FY ended March 31, 2026, on equity shares of face value ₹1.00 each fully paid up.

Cost Auditor Remuneration

R. Nanabhoy & Co. (Firm Registration No. 000010) appointed as cost auditors for FY ending March 31, 2027 at remuneration of ₹1 million plus applicable GST and out-of-pocket expenses.

Non-Executive Director Commission

Commission not exceeding 1% of net profits per annum or ₹40 million aggregate per financial year for 5 years from April 1, 2026 to March 31, 2031.

Results Declaration

The results were announced on August 11, 2026, based on Consolidated Scrutinizer's Report. Results are available on company website www.zyduslife.com and at registered office.